Chinese PLA General

Company snapshot

Chinese PLA General is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Liver Cancer, Gastric Cancer, Colorectal Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2), phase 2 (2).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chinese PLA General. Not investment advice.

• What is Chinese PLA General?

  Chinese PLA General is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Liver Cancer, Gastric Cancer, Colorectal Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entit

• Is Chinese PLA General publicly traded?

  Chinese PLA General appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chinese PLA General develop or market?

  We link 9 drug profile(s) where Chinese PLA General is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chinese-pla-general-hospital#company-drugs.

• What are the latest developments for Chinese PLA General?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chinese PLA General focus on?

  Chinese PLA General focuses on Hepatocellular Carcinoma, Liver Cancer, Gastric Cancer based on our analysis of their pipeline programs and drug development activities.